Skip to Main Content

Paper Details

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.
Clin Cancer Res
19
2015
C482R, KDR, Pazopanib, VEGF receptor, VEGFR, VEGFR2, VEGFR2 kinase, advanced solid tumor, cancer, patients, pazopanib, pharmacogenetic markers, renal carcinoma, rs34231037, sVEGFR2, serum VEGFR2, systemic endothelial cells, vascular VEGFR2
Author NameAffiliation
Ching-Yu ChengUniversity of Maryland
Ching-Yu ChengUniversity of Maryland
Eric R GamazonUniversity of Chicago
Eric R GamazonUniversity of Chicago
Lon R Cardon
Jeffrey R O'ConnellUniversity of Maryland
Jeffrey R O'ConnellUniversity of Maryland
Nancy J CoxUniversity of Chicago, Illinois. Comprehensive Cancer Center
Nancy J CoxUniversity of Chicago, Illinois. Comprehensive Cancer Center
Braxton D MitchellUniversity of Maryland
Mark J RatainUniversity of Chicago, Illinois. Comprehensive Cancer Center
Alan R ShuldinerUniversity of Maryland, Maryland. Geriatric Research and Education Clinical Center, Baltimore Veterans Administration Medical Center
Alan R ShuldinerUniversity of Maryland, Maryland. Geriatric Research and Education Clinical Center, Baltimore Veterans Administration Medical Center
  • 1 - 13

Datasets

Release 1.2